Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

309 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Overcoming challenges in conducting early phase breast cancer prevention trials: Bazedoxifene and conjugated estrogens vs waitlist control.
Fabian CJ, Mudaranthakam DP, Gajewski B, Young K, Winblad O, Khan SA, Garber JE, Esserman LJ, Yee LD, Nye L, Powers KR, Ranallo L, Kreutzjans AL, Pittman K, Altman C, Metheny T, Zelenchuk A, Komm BS, Kimler BF. Fabian CJ, et al. Among authors: esserman lj. Contemp Clin Trials. 2024 Nov;146:107697. doi: 10.1016/j.cct.2024.107697. Epub 2024 Sep 17. Contemp Clin Trials. 2024. PMID: 39293780 Free article.
Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial.
Johansson A, Dar H, Nordenskjöld A, Perez-Tenorio G, Tobin NP, Yau C, Benz CC, Esserman LJ, van 't Veer LJ, Nordenskjöld B, Stål O, Fornander T, Lindström LS. Johansson A, et al. Among authors: esserman lj. J Natl Cancer Inst. 2024 Dec 4:djae268. doi: 10.1093/jnci/djae268. Online ahead of print. J Natl Cancer Inst. 2024. PMID: 39656627
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
Rugo HS, Campbell M, Yau C, Jo Chien A, Wallace AM, Isaacs C, Boughey JC, Han HS, Buxton M, Clennell JL, Asare SM, Steeg K, Wilson A, Singhrao R, Matthews JB, Perlmutter J, Fraser Symmans W, Hylton NM, DeMichele AM, Yee D, Van't Veer LJ, Berry DA, Esserman LJ. Rugo HS, et al. Among authors: esserman lj. Breast Cancer Res Treat. 2024 Dec 3. doi: 10.1007/s10549-024-07555-9. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39625569
Tumor Morphology for Prediction of Poor Responses Early in Neoadjuvant Chemotherapy for Breast Cancer: A Multicenter Retrospective Study.
Li W, Le NN, Nadkarni R, Onishi N, Wilmes LJ, Gibbs JE, Price ER, Joe BN, Mukhtar RA, Gennatas ED, Kornak J, Magbanua MJM, Van't Veer LJ, LeStage B, Esserman LJ, Hylton NM. Li W, et al. Among authors: esserman lj. Tomography. 2024 Nov 20;10(11):1832-1845. doi: 10.3390/tomography10110134. Tomography. 2024. PMID: 39590943 Free PMC article.
Validation study of risk-reduction activities after personalized breast cancer education tool in the WISDOM study.
Wang T, Che M, Huilgol YS, Keane H, Goodman D, Soonavala R, Ozanne E, Shieh Y, Belkora JK, Fiscalini AS; Athena Breast Health Network Investigators and Advocate Partners; Esserman LJ. Wang T, et al. Among authors: esserman lj. NPJ Breast Cancer. 2024 Oct 14;10(1):90. doi: 10.1038/s41523-024-00681-z. NPJ Breast Cancer. 2024. PMID: 39397069 Free PMC article.
When is prostate cancer really cancer?
Cooperberg MR, Braun AE, Berlin A, Kibel AS, Eggener SE; CANCER-GG1 Writing Group. Cooperberg MR, et al. J Natl Cancer Inst. 2024 Oct 1:djae200. doi: 10.1093/jnci/djae200. Online ahead of print. J Natl Cancer Inst. 2024. PMID: 39350309
309 results